Septic Shock News and Research

RSS

Some nutritional supplements may help prevent or mitigate COVID-19 severity

A new study in the Journal of dietary supplements shows that nutritional supplements, including several vitamins and the mineral zinc, may be useful in preventing the infection or reducing its severity if caught.

22 Feb 2021

Organ transplant patient dies after receiving Covid-infected lungs

Doctors say a woman in Michigan contracted covid-19 and died last fall two months after receiving a tainted double-lung transplant from a donor who turned out to harbor the virus that causes the disease — despite showing no signs of illness and initially testing negative.

22 Feb 2021

Study assesses link between secondary bloodstream infection and severe COVID-19

People with severe COVID-19 and a secondary blood infection were significantly sicker upon hospital admission, had longer hospital stays and poorer outcomes, according to a Rutgers study.

23 Dec 2020

Study: COVID-19 patients have greater risk of health problems, mortality than those with flu

Almost a year ago, COVID-19 began its global rampage, going on to infect about 69.5 million people and kill about 1.6 million as of early this month.

15 Dec 2020

Low testosterone can increase risk of severe COVID-19 in males

Researchers from the USA and Saudi Arabia describe the direct correlation between testosterone levels, inflammatory cytokines, disease progression, and worse outcomes in male COVID-19 patients.

4 Dec 2020

Septic shock and pneumonia triggered by SARS-CoV-2 could be treated by radiation-activated MSCs

This study, published in the journal Cells, is based on others (all of which employed experimental models) previously conducted by researchers at the Biomedical Research Centre of the University of Granada, the ‘López-Neyra’ Institute of Parasitology and Biomedicine, and the ‘Virgen de las Nieves’ University Hospital in Granada

23 Nov 2020

Drugs targeting neutrophils could reduce ARDS in severe COVID-19

Scientists in Taiwan recently published a report on their use of anti-neutrophil strategies to treat acute respiratory distress syndrome (ARDS) – a life-threatening condition that can arise in critical COVID-19 cases – in the journal Frontiers in Pediatrics.

15 Nov 2020

DNase coated melanin-like nanospheres for sepsis treatment in severe COVID

As the treatment of severe COVID-19 is very difficult, the researchers from the Korea Research Institute of Biosciences and Biotechnology (KRIBB) suggested that DNase-1 can be utilized to dissolve the neutrophil extracellular traps (NETs), hence halting the further progression of COVID-19.

27 Oct 2020

Template for COVID-19 management in a rural health system

As the COVID-19 pandemic continues to challenge existing health networks, a new study published on the preprint server medRxiv in October 2020 reports on a strategy to address existing health care disparities in rural and urban areas of the USA. This should draw attention to the need for more such systems to ensure proper rural healthcare in the current and future pandemics.

20 Oct 2020

SARS-CoV-2 and anti-COVID-19 drugs activate Kaposi sarcoma-associated herpesvirus

A new study published on the preprint server bioRxiv* aimed to investigate the impacts of COVID-19 on people with various illnesses. Specifically, the researchers at the Rockefeller Cancer Institute, and the University of Arkansas for Medical Sciences wanted to see the effects of COVID-19 on patients with cancer and other infectious diseases.

6 Oct 2020

Shorter time from COVID-19 symptom onset to hospitalization linked to disease severity, death

New research presented at this week's ESCMID Conference on Coronavirus Disease (ECCVID, held online) shows that a shorter time from symptom onset to hospitalization is associated with more serious disease and death in patients with COVID-19.

26 Sep 2020

Scientists investigate active plasma metabolite of remdesivir in SARS-CoV-2 mouse model

Using mouse models, scientists have investigated the active plasma metabolite of remdesivir, GS-441 524, and hydroxychloroquine as possible drug candidates in COVID-19. The research shows GS-441 524 could be an effective therapeutic drug against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while at the same time discounting hydroxychloroquine as a reliable anti-viral.

20 Sep 2020

Earlier treatment with steroids reduces adverse outcomes in patients with septic shock

Some critically ill patients with septic shock need medications called vasopressors to correct dangerously low blood pressure.

14 Sep 2020

COVID-19 in pregnancy doubles odds of preterm delivery

The COVID-19 pandemic is continuing to cause huge social, economic, and health-related costs throughout the world, especially in Spain. Clinicians are still coming to terms with the range of health conditions wrought by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). A new study published on the preprint server medRxiv* in September 2020 shows that this infection results in fetal and maternal complications.

9 Sep 2020

COVID-19 is not characterized by a cytokine storm, shows study

Does the COVID-19 cytokine storm exist? Inflammatory proteins, also known as cytokines, play a crucial role in the immune response. If this immune response is too strong, a phenomenon known as "cytokine storm", it can cause harm to the patient.

5 Sep 2020

Surgical patients with low health literacy more likely to experience postoperative infection

Surgical patients are more likely to experience a postoperative infection if they have low health literacy, which is a limited capacity to understand and act on health information, according to results of a new study presented at the American College of Surgeons 2020 Quality and Safety Conference VIRTUAL.

24 Aug 2020

Photonics-based device could help COVID-19 patients with adequate treatments

Few could have foreseen the considerable impact that SARS-CoV-2 has had so far and is still having worldwide. Numbers continue to escalate and the complexity of the COVID-19 symptoms have hindered all efforts to optimize its treatment.

3 Aug 2020

SphingoTec launches point-of-care test for bio-ADM, a biomarker for life threatening endothelial dysfunction

Diagnostics company SphingoTec GmbH today announced the launch of its IB10 sphingotest® bio-ADM®, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of Bioactive Adrenomedullin. Blood levels of bio-ADM® reflect in real-time the functional status of the endothelium, the inner cell sheet of blood vessels.

24 Jul 2020

SphingoTec introduces a CE-IVD-marked point-of-care test to determine blood levels of bio-ADM

Diagnostics company SphingoTec GmbH today announced the launch of its IB10 sphingotest bio-ADM, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of Bioactive Adrenomedullin (bio-ADM).

22 Jul 2020

Clots, COVID-19 and survival

The novel coronavirus, now known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), that causes COVID-19 disease, was first reported in Wuhan, Hubei Province of China in late December 2019. Since then, it has infected a large population across the world with the current number of SARS-CoV-2 infections standing at over 13 million and COVID-19 disease having killed over 571,000 individuals.

13 Jul 2020